Autexun (002227.SZ): Net loss in the first quarter was 14.5987 million yuan

Gelonghui April 25 | Autexun (002227.SZ) announced the first quarter report of 2024. The operating income during the reporting period was 67.0647 million yuan, a year-on-year decrease of 1.15%; the net profit attributable to shareholders of the listed company was -14.5987 million yuan; Net profit after non-recurring gains and losses for shareholders of listed companies was -15.7862 million yuan; basic earnings per share -0.0589 yuan.

Gelonghui April 25 | Autexun (002227.SZ) announced the first quarter report of 2024. The operating income during the reporting period was 67.0647 million yuan, a year-on-year decrease of 1.15%; the net profit attributable to shareholders of the listed company was -14.5987 million yuan; Net profit after non-recurring gains and losses for shareholders of listed companies was -15.7862 million yuan; basic earnings per share -0.0589 yuan.

Like (0)
Previous April 25, 2024 7:59 pm
Next April 25, 2024 7:59 pm

Related posts

  • The vaccine market is turbulent, and Zhifei Biotech’s “big brother” status is difficult to maintain

    For stock trading, please read Jin Qilin analyst research reports. They are authoritative, professional, timely and comprehensive, helping you to tap potential theme opportunities! Source: Financial Investment News Financial Investment News reporter Chen Yuhe After Zhifei Biotechnology (300122), the “vaccine brother”, released its 2023 annual report, its stock price continued to fall. Some market participants attributed its falling stock price to its high reliance on foreign supplies. Business is linked to the gradually revealed decline in performance. In recent years, the vaccine market has been changing. On the one hand, the once \”hot-selling\” nine-price HPV vaccine is no longer hard to find. On the other hand, various good news about the domestically produced nine-price HPV vaccine continue to spread, attracting a lot of attention. Institutions pay great attention to its listing process. Zhifei Bio\’s growth capability indicators Zhi Fei Bio\’s stock price continues to fall. The annual report shows that in 2023, Zhi Fei Bio\’s operating income was 52.918 billion yuan, a year-on-year increase of 38.3%; it achieved net profit attributable to the parent company of 8.07 billion yuan, a…

    US Stocks Focus April 25, 2024
  • SEBI panel proposes changes to BRSR framework

    A SEBI committee has suggested changes to the BRSR, or Business Responsibility and Sustainability Reporting, framework.

    US Stocks Focus May 23, 2024
  • European stocks opened mixed, with the Stoxx Europe 50 index down 0.10%

    .app-kaihu-qr{text-align: center;padding: 20px 0;}.app-kaihu-qr span{font-size: 18px; line-height: 31px;display: block;}.app-kaihu-qr img{width: 170px;height: 170px;display: block;margin: 0 auto;margin-top: 10px;}The stock market is picking up, open an account first to buy stocks at the bottom! Smart fixed investment, conditional orders, individual stock radar…given to you>> .appendQr_wrap{border:1px solid #E6E6E6;padding:8px;} .appendQr_normal{float:left;} .appendQr_normal img{width:74px;} .appendQr_normal_txt{ float:left;font-size:20px;line-height:74px;padding-left:20px;color:#333;} Massive information and accurate interpretation, all in Sina Finance APP Editor-in-Chief: Guo Mingyu

    US Stocks Focus April 25, 2024
  • Yongxin Shares: Net profit in the first quarter of 2024 was 86.4236 million yuan, a year-on-year increase of 10.86%

    Yongxin Shares (002014) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 835 million yuan, a year-on-year increase of 6.34%; net profit attributable to the parent company was 86.4236 million yuan, a year-on-year increase of 10.86%; non-net profit after deducting 80.7743 million yuan, a year-on-year increase of 5.50%; generated from operating activities Net cash flow was -71.7951 million yuan, compared with -114 million yuan in the same period last year; during the reporting period, Yongxin\’s basic earnings per share was 0.14 yuan, and the weighted average return on net assets was 3.62%.

    US Stocks Focus April 25, 2024
  • Indegene IPO subscribed 69.70 times as institutions bid aggressively

    The initial public offering of Indegene saw a robust response from all category investors, as the issue was subscribed 69.70 times, thanks to QIBs.

    US Stocks Focus May 8, 2024
  • SBI market cap hits ₹8 lakh crore, surpasses milestone amid record share price surge

    The State Bank of India (SBI) ‘s market capitalisation crossed the ₹8 lakh crore mark on Monday after the bank’s shares surged to a record high of ₹907.

    US Stocks Focus June 3, 2024